Eosinophilic Granulomatosis With Polyangiitis

Eosinophilic Granulomatosis With Polyangiitis (EGPA), formerly Churg-Strauss syndrome, is a rare autoimmune disease. It causes inflammation of small and medium blood vessels (vasculitis) throughout the body. This inflammation can restrict blood flow and damage organs like the lungs, skin, nerves, and heart, leading to a variety of symptoms.

What is Eosinophilic Granulomatosis With Polyangiitis?

Eosinophilic Granulomatosis With Polyangiitis (EGPA), previously known as Churg-Strauss syndrome, is a rare autoimmune condition. It causes inflammation in the walls of small and medium-sized blood vessels (vasculitis) throughout the body. This inflammation can damage various organs, most commonly the lungs, skin, and nerves, but also the heart, digestive system, and kidneys.

EGPA is considered an autoimmune disease, meaning the body's immune system mistakenly attacks its own healthy tissues. This leads to widespread inflammation. A key feature of EGPA is an unusually high number of white blood cells called eosinophils in the blood and affected tissues. The condition often develops in three stages, though not everyone experiences all of them or in this exact order. The first stage often involves allergic symptoms like asthma and hay fever (allergic rhinitis). The second stage is marked by a high count of eosinophils, which can infiltrate and damage organs. The third stage involves widespread blood vessel inflammation (vasculitis), leading to more severe organ damage. Because EGPA can affect many different parts of the body, its symptoms can vary greatly from person to person. It is a chronic condition that requires ongoing medical management to control inflammation and prevent organ damage.

Symptoms

Symptoms of Eosinophilic Granulomatosis With Polyangiitis (EGPA) can vary widely because the condition affects many organs. Common early signs often include new or worsening asthma, chronic sinus inflammation (sinusitis), and hay fever (allergic rhinitis). Later symptoms can involve skin rashes, nerve damage, muscle and joint pain, and general signs like fever, fatigue, and unexplained weight loss.

The symptoms of EGPA often appear in stages. Many people first experience severe asthma that develops in adulthood or worsens significantly. They may also have persistent nasal polyps, chronic sinus infections, and allergic rhinitis, which causes sneezing, runny nose, and congestion. As the disease progresses, inflammation of blood vessels can lead to more widespread issues. You might notice skin changes, such as rashes, bumps, or sores. Nerve damage (peripheral neuropathy) is common, causing numbness, tingling, weakness, or sharp pain, especially in the hands and feet. Other possible symptoms include muscle and joint pain, fever, extreme tiredness (fatigue), and unintentional weight loss. Less commonly, EGPA can affect the heart, leading to chest pain or shortness of breath, or the digestive system, causing abdominal pain or bleeding. Kidney problems can also occur, though they are less frequent.

Causes & risk factors

The exact cause of Eosinophilic Granulomatosis With Polyangiitis (EGPA) is not fully understood, but it is known to be an autoimmune disease. This means the body's immune system mistakenly attacks its own healthy cells and tissues, causing inflammation. While the precise trigger is unknown, certain factors, such as a history of asthma or allergies, are considered risk factors for developing the condition.

EGPA is not contagious and does not run in families in a predictable way. Researchers believe a combination of genetic predisposition and environmental factors might play a role in triggering the immune system's abnormal response. However, specific genes or environmental triggers have not been definitively identified. The primary risk factors for developing EGPA are having a history of allergic conditions. These include asthma, which is present in almost all people with EGPA, and other allergies like allergic rhinitis or chronic sinusitis. It's important to note that while these conditions are risk factors, most people with asthma or allergies will never develop EGPA. The immune system's overreaction leads to the production of certain antibodies and an increase in eosinophils, a type of white blood cell. These cells contribute to the inflammation and damage seen in various organs throughout the body.

How it's diagnosed

Diagnosing Eosinophilic Granulomatosis With Polyangiitis (EGPA) can be challenging due to its rarity and varied symptoms, often requiring a combination of tests. A doctor will typically start with a physical exam and review your medical history, especially regarding asthma and allergies. Blood tests, imaging scans, and tissue biopsies are crucial for confirming the diagnosis and assessing organ involvement.

Blood tests are a key part of the diagnostic process. They can reveal a high count of eosinophils, which are often significantly elevated in people with EGPA. Other blood tests look for markers of inflammation, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Some people with EGPA may also have specific antibodies called anti-neutrophil cytoplasmic antibodies (ANCAs), though these are not always present. Imaging studies help doctors assess which organs are affected. A chest X-ray or computed tomography (CT) scan of the chest can show inflammation in the lungs. Other imaging, like CT scans of the sinuses or abdomen, may be used depending on your symptoms. Nerve conduction studies might be performed if nerve damage is suspected. The most definitive way to diagnose EGPA is through a biopsy of an affected tissue, such as skin, nerve, lung, or kidney. A small sample of tissue is removed and examined under a microscope for signs of inflammation, damaged blood vessels (vasculitis), and the presence of eosinophils and granulomas (small clumps of immune cells).

Treatment options

Treatment for Eosinophilic Granulomatosis With Polyangiitis (EGPA) aims to reduce inflammation, suppress the overactive immune system, and prevent organ damage. Corticosteroids, such as prednisone, are usually the first line of treatment to control acute inflammation. Depending on the severity and specific organ involvement, other immunosuppressive medications or biologic drugs may be added to achieve remission and reduce steroid dependence.

Corticosteroids are highly effective at quickly reducing inflammation and are typically prescribed in high doses initially. Once symptoms are under control, the dose is gradually reduced. However, long-term use of high-dose corticosteroids can have significant side effects, so doctors often try to minimize their use over time. For more severe cases, or to help reduce the need for high-dose steroids, other immunosuppressant drugs may be used. These include medications like cyclophosphamide, azathioprine, or methotrexate, which work by further suppressing the immune system. The choice of medication depends on the severity of the disease, which organs are affected, and individual patient factors. Newer biologic drugs, such as rituximab or mepolizumab, are also used, especially for people who do not respond well to initial treatments or who experience frequent relapses. Rituximab targets specific immune cells, while mepolizumab targets eosinophils. In very severe, life-threatening situations, a procedure called plasma exchange (plasmapheresis) might be considered to remove harmful antibodies from the blood.

Recovery & outlook

Eosinophilic Granulomatosis With Polyangiitis (EGPA) is a chronic condition that requires ongoing management, but with early diagnosis and appropriate treatment, many people can achieve remission. While relapses are possible, consistent medical care helps control symptoms and prevent severe organ damage. The outlook has significantly improved over the years due to advancements in treatment, allowing many individuals to lead full and active lives.

The goal of treatment is to induce remission, meaning the disease activity is controlled and symptoms improve. Once remission is achieved, maintenance therapy is usually continued with lower doses of medications to prevent relapses. Regular follow-up appointments and monitoring are essential to adjust treatment as needed and to watch for any signs of disease flare-ups. While EGPA can be life-threatening if left untreated, particularly due to heart or kidney involvement, modern treatments have dramatically improved the prognosis. The severity of the disease and which organs are affected play a significant role in an individual's long-term outlook. For example, heart involvement can indicate a more serious course. Living with EGPA often involves managing medications and potential side effects, as well as coping with chronic symptoms like fatigue. Support groups and lifestyle adjustments can be helpful. It's crucial to work closely with your healthcare team to manage the condition effectively and maintain the best possible quality of life.

When to see a doctor

You should see a doctor if you experience new or worsening symptoms that could suggest Eosinophilic Granulomatosis With Polyangiitis (EGPA), especially if you have a history of asthma or allergies. Red-flag signs include severe or uncontrolled asthma, persistent sinus issues, new numbness or weakness, unexplained fever, significant weight loss, or severe abdominal pain. Early medical attention is crucial for timely diagnosis and effective treatment.

If you have asthma that suddenly becomes much worse, or if you develop new asthma symptoms as an adult, it's important to consult your doctor. Similarly, persistent or severe sinus problems, such as chronic infections or nasal polyps that don't respond to usual treatments, warrant medical evaluation. Pay close attention to symptoms that suggest nerve damage, such as new or increasing numbness, tingling, or weakness in your hands or feet. Unexplained general symptoms like ongoing fever, extreme fatigue, or unintended weight loss should also prompt a visit to your doctor. Seek immediate medical attention if you experience severe chest pain, sudden shortness of breath, severe abdominal pain, or any signs of internal bleeding. These could indicate serious organ involvement requiring urgent care. Always discuss any new or concerning symptoms with a qualified clinician.

Frequently asked questions

Is Eosinophilic Granulomatosis With Polyangiitis (EGPA) a type of cancer?

No, EGPA is not a cancer. It is an autoimmune disease where the immune system mistakenly attacks healthy blood vessels and tissues, causing inflammation. While it involves an increase in certain white blood cells (eosinophils), this is due to an inflammatory response, not a cancerous growth.

How rare is EGPA?

EGPA is considered a very rare disease. While exact numbers can vary, it is estimated to affect only a few people per million each year. Its rarity often makes diagnosis challenging, as many healthcare providers may not encounter it frequently.

Can EGPA be cured?

Currently, there is no cure for EGPA. However, with appropriate and ongoing treatment, many people can achieve remission, meaning the disease activity is controlled and symptoms improve significantly. Treatment focuses on managing symptoms, preventing organ damage, and reducing the frequency and severity of relapses.

Are there any dietary restrictions for people with EGPA?

There are no specific dietary restrictions universally recommended for EGPA. However, some people with EGPA may have food sensitivities or allergies that could worsen their symptoms. It's always best to discuss any dietary concerns or potential changes with your doctor or a registered dietitian to ensure it's safe and beneficial for your specific condition.

What is the difference between EGPA and other forms of vasculitis?

EGPA is a specific type of vasculitis characterized by inflammation of small and medium blood vessels, often accompanied by severe asthma and a high count of eosinophils. Other forms of vasculitis may affect different sizes of blood vessels, have different causes, or involve different types of immune cells, leading to distinct symptom patterns and treatment approaches.

Can EGPA affect children?

While EGPA can occur at any age, it is extremely rare in children. It most commonly affects adults, typically appearing between the ages of 30 and 50. When it does occur in children, diagnosis can be particularly challenging due to its rarity in this age group.

Sources

• MedlinePlus — Eosinophilic Granulomatosis With Polyangiitis
• Mayo Clinic — Eosinophilic Granulomatosis With Polyangiitis
• Cochrane Library — Eosinophilic Granulomatosis With Polyangiitis